2015
DOI: 10.1152/ajplung.00237.2015
|View full text |Cite
|
Sign up to set email alerts
|

Revascularization of decellularized lung scaffolds: principles and progress

Abstract: Stabler CT, Lecht S, Mondrinos MJ, Goulart E, Lazarovici P, Lelkes PI. Revascularization of decellularized lung scaffolds: principles and progress.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
34
0
2

Year Published

2016
2016
2019
2019

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 49 publications
(36 citation statements)
references
References 128 publications
0
34
0
2
Order By: Relevance
“…However, the studies reviewed herein also suggest that ECM scaffolds have potential as cell delivery scaffolds, although this significantly increases treatment costs and has a more difficult regulatory pathway as a combination product. More long term development could result in the use of decellularized ECM for whole organ engineering [9295]; however, this increase in complexity creates numerous more challenges that must be overcome, including creating fully functional constructs and preventing thrombosis in the vasculature [96, 97]. …”
Section: Current Challenges and Future Opportunitiesmentioning
confidence: 99%
“…However, the studies reviewed herein also suggest that ECM scaffolds have potential as cell delivery scaffolds, although this significantly increases treatment costs and has a more difficult regulatory pathway as a combination product. More long term development could result in the use of decellularized ECM for whole organ engineering [9295]; however, this increase in complexity creates numerous more challenges that must be overcome, including creating fully functional constructs and preventing thrombosis in the vasculature [96, 97]. …”
Section: Current Challenges and Future Opportunitiesmentioning
confidence: 99%
“…This long track record and acceptance by clinicians is indicative of the promise of new ECM-based biomaterials that can be applied to repair or regenerate damaged, missing, or dysfunctional tissues and organs without activating host immune response, [1] or even serve as model materials for in vitro healthy or diseased tissue modeling. [11,12] Despite dECM’s demonstrated advantages as a raw material and promise for use in an extensive range of tissue and organ targets including but not limited to: heart, [13] muscle, [1,14] nerve, [15] liver, [3,16,17] lung, [18,19] kidney, [4,20] bone, [21] skin, [22] bladder, [23] ovary, [24] and penis, [25] the existing processing routes for creating diverse sets of clinically practical, tissue-specific dECM-based biomaterials remain limited.…”
Section: Introductionmentioning
confidence: 99%
“…It seems clear, however, that the differentiation and maturation of cells in the reseeded graft need to be improved. According to Stabler et al (2015), reconstitution of physiological pulmonary vasculature in its entirety will significantly improve the generation of whole lungs through bioengineering organs. Therefore, it could be expected that variations in arterial and alveolar pressures could influence cell adhesion, considering that a reduced flow through the lung circuit would decrease cell distribution.…”
Section: Discussionmentioning
confidence: 99%